GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...
GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...
The Fresh Market’s most recent store opening in the Chicago neighborhood of Lincoln Park took the place of a Dom’s Kitchen ...
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
MT Newswires on MSN1d
European Equities Close Higher in Thursday Trading; EU GDP Rises in Q3The European stock markets closed higher in Thursday trading as The Stoxx Europe rose 1.08%, Germany's DAX climbed 1.26%, the FTSE in London was up 0.51%, France's CAC advanced 1.32%, and the Swiss ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback